Dyne Therapeutics Inc (DYN)

May 09, 2025

H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) - GuruFocus

May 09, 2025

May 09, 2025

Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus

May 09, 2025

May 09, 2025

RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com

May 09, 2025

May 09, 2025

H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus

May 09, 2025

May 09, 2025

Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus

May 09, 2025

May 09, 2025

Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus

May 09, 2025

May 08, 2025

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

May 08, 2025

May 08, 2025

Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

May 08, 2025

Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq

May 08, 2025

May 08, 2025

Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus

May 08, 2025

May 08, 2025

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus

May 08, 2025

May 08, 2025

Dyne Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey

Apr 25, 2025

Apr 25, 2025

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance

Apr 25, 2025

Apr 24, 2025

11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics stock rises on orphan drug status - Investing.com

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics Receives European Medicines Agency (EMA) Orpha - GuruFocus

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy - marketscreener.com

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - The Manila Times

Apr 24, 2025

Apr 24, 2025

Dyne Therapeutics Receives European Medicines Agency (EMA) - GlobeNewswire

Apr 24, 2025

Apr 24, 2025

Breakthrough DMD Treatment DYNE-251 Wins Crucial EU Orphan Status as Phase 1/2 Trial Shows Promise - Stock Titan

Apr 24, 2025

Apr 22, 2025

Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st

Apr 22, 2025

Apr 21, 2025

Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha

Apr 21, 2025

Apr 17, 2025

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News

Apr 17, 2025

Apr 16, 2025

More C-suite changes at Dyne - BioCentury

Apr 16, 2025

Apr 15, 2025

Dyne Therapeutics reshapes leadership team ahead of drug launches By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus

Apr 15, 2025

Apr 15, 2025

Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus

Apr 15, 2025

Apr 15, 2025

Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com

Apr 15, 2025

Apr 15, 2025

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - The Manila Times

Apr 15, 2025

Apr 14, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 14, 2025

Apr 14, 2025

Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan

Apr 14, 2025

Apr 11, 2025

Dyne wins new Outperform at BMO on prospects for lead drug - MSN

Apr 11, 2025

Apr 10, 2025

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo

Apr 10, 2025

Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025

Apr 04, 2025

Ex-Dyne team members reconvene at Crescent - biocentury.com

Apr 04, 2025

Apr 03, 2025

RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener

Apr 03, 2025

Apr 02, 2025

FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech

Apr 02, 2025

Apr 01, 2025

Oversold Conditions For Dyne Therapeutics - Nasdaq

Apr 01, 2025

Apr 01, 2025

FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech

Apr 01, 2025

Mar 27, 2025

Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals

Mar 27, 2025